Maravai LifeSciences Holdings, Inc. MRVI Cygnus — Cost of revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Maravai LifeSciences Holdings, Inc.'s cygnus — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Maravai LifeSciences Holdings, Inc.'s cygnus — cost of revenue?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — cost of revenue of $2.16M in Q1 2026.
- How has Maravai LifeSciences Holdings, Inc.'s cygnus — cost of revenue changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s cygnus — cost of revenue decreased by 22.8% year-over-year, from $2.8M to $2.16M.
- What does cygnus — cost of revenue mean?
- Represents the direct costs incurred to produce and deliver the products and services sold by the Biologics Safety Testing segment. This includes raw materials, direct labor, and manufacturing overheads directly tied to revenue generation. It is a key metric for evaluating the segment's gross margin and production efficiency.